Vaccine-induced and hybrid immunity to SARS-CoV-2 after three or four doses of BNT162b2 - results from 22 months follow-up of a healthcare workers cohort, Israel, 2020-2022
Description
CONCLUSION: Three BNT162b2 doses provide long-term immunogenicity comparable to breakthrough infection post-dose two. Dose four transiently increases IgG levels and may be especially important for providing additional protection to vulnerable
